Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Edition  2017: Volume 22/ Issue 2 Article 3
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 22, Issue 2, 12 January 2017
Surveillance and outbreak report
Hauser, Hofmann, Hanke, Bremer, Bartmeyer, Kuecherer, and Bannert: National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014

+ Author affiliations

Citation style for this article: Hauser A, Hofmann A, Hanke K, Bremer V, Bartmeyer B, Kuecherer C, Bannert N. National molecular surveillance of recently acquired HIV infections in Germany, 2013 to 2014. Euro Surveill. 2017;22(2):pii=30436. DOI:

Received:01 February 2016; Accepted:23 August 2016


Continuous molecular HIV surveillance provides valuable public health information concerning the transmission of drug-resistant viruses and the dynamics of currently circulating variants. Transmitted drug resistance (TDR) has significant clinical consequences as it is associated with an increase in the failure rate of antiretroviral therapy (ART) [1]. With prevalence of TDR (at least one resistance mutation) ranging between 10% and 15% in several European countries and in North America [2-6], the problem is of substantial concern. Genotypic resistance testing is therefore recommended before commencing first-line treatment [7]. The prevalence of TDR in a country is determined by the history of clinical therapy regimens and the failures resulting from resistance. TDR can vary depending on transmission route, country of origin of the patient and country of infection [6]. From a virological perspective, TDR is largely determined by the persistence of the associated mutation(s). Persistence of those mutations depends mainly on the fitness costs to the virus and on the viral genetic background (e.g. chance of compensatory mutations) [8].

Knowledge of currently circulating HIV subtypes in a country and the dynamics of their spread is of epidemiological and clinical relevance. This information affects the safety and accuracy of HIV diagnostics and is valuable for HIV prevention and vaccine development.

The objective of this study was to determine TDR and HIV-1 subtypes in a substantial subset of new HIV-1 infections diagnosed in 2013 and 2014 in Germany. We intended to examine transmissions from a restricted period of time and therefore, only recently acquired infections among the newly diagnosed cases were included. We aimed to analyse TDR and transmitted HIV-1 subtypes in the main transmission groups: men who have sex with men (MSM), persons with heterosexual contact (HET) and people who inject drugs (PWID), considering sex and origin of the infected individual and place of infection.


Clinical samples

The data protection officer of the RKI and the German Federal Commissioner for Data Protection and Freedom of Information approved the study protocol (III-401/008#0016).

RNA isolation and HIV sequencing

HIV RNA from 4 x 100 µL DSS was extracted according to the manufacturer’s instructions with the manual NucliSense Magnetic Extraction method for samples collected in 2013 or the automated Biomerieux EasyMag platform for samples collected in 2014 (both bioMerieux, Capronne, France). Viral RNA was quantified using an in house LTR RT-TaqMan PCR according to a modified protocol [9]. As concentration controls, serial dilutions of the IIIB strain of HIV-1 in human HIV-negative plasma was dropped onto filter cards (DPS standard). Samples were analysed using a newly designed HIV-1 group M generic RT-PCR system (in house pol RT-PCR) covering the genomic region of HIV-1 protease (AS9–99) and reverse transcriptase (AS1–252) including all resistance-associated positions. The in house pol RT-PCR assay consists of two pol RT-PCRs yielding two overlapping amplicons: a fragment 1 of 576 bp (primer_A: CCCTCARATCACTCTTTggCARCgA, position 2,252–2,276; Primer_B: CCTAATTgAACYTCCCARAARTCYTgAgT, position 2,799–2,827) and a second fragment 2 of 718 bp (Primer_C: AAACAATggCCATTRACAgARgA, position 2,613–2,636; primer_D: CTAAYTTYTgTATRTCATTgACAgTCCA, position 3,303–3,330). All nucleotide positions refer to sequence of the HXB2 genome (accession number K03455). The detection limit of the in house pol RT-PCR was shown to be equivalent to 1,000 copies/mL DPS standard (highest dilution resulting in 100% positive PCR outcome). Population-based sequencing was performed and a consensus sequence from both fragments was obtained.

HIV-1 subtyping

The HIV-1 subtype was assigned by applying the REGA HIV-1 subtyping tool (REGA HIV Subtyping Tool Version 3.0) and COMET HIV-1 (Version 1.0) [10] to the pol sequence. Only subtype classifications based on bootstrap values of > 70% in the tree topology were taken into account. In cases where a subtype or circulating recombinant form (CRF) was not assigned by either subtyping tool, the strain was classified as unique recombinant form (URF). In addition, a distance-based neighbour-joining method and bootstrap (PHYLIP version 3.6) was calculated using an extended panel of subtype reference sequences from the Los Alamos HIV sequence database.

HIV drug resistance interpretation and calculation of the prevalence of transmitted drug resistance

The World Health Organization (WHO)’s surveillance drug resistance mutations (SDRM) list was used to interpret TDR [11]. Levels of expected resistance to each of the three drug classes nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI) and protease inhibitors (PI) as mono, dual or triple class resistance were predicted using the Stanford algorithm (version 7.0). Three levels of resistance were scored: high (R), intermediate (I, intermediate and low), sensitive (S, potentially resistant and sensitive).

Statistical analysis

Descriptive statistics for continuous variables were calculated as medians and interquartile ranges (IQR). Differences in proportions, odds ratios (OR) and 95% confidence intervals (CI) were assessed by two-sided Fisher’s exact test using EPICALC 2000 software (version 1.02; Gilman and Myatt 1997). A two-sided p value ≤ 0.05 was considered significant.


Characterisation of the study population

In 2013 and 2014, a total of 6,371 DSS prepared from residual serum of newly HIV-diagnosed cases were submitted to the RKI along with the anonymous report. Of these, 2,034 (32%) were serologically classified as recent HIV infections using the BED-CEIA. The viral load was reported for 700 and a CD4+ T-cell count for 543 of the 2,034 specimens. Specimens with CD4+ T-cell counts < 200 cells/µL (n = 108) or viral loads < 400 copies/mL (n = 50) or both (n=8) were reclassified as 'long-standing infections' and, together with repeatedly reported cases (n = 71), excluded, resulting in 1,797 DSS. Sufficient material (four serum spots à 100 µL) was available for 1,387 of those specimens. The pol RT-PCR amplification and sequencing was successful in 809 samples; these represented the final study panel of recent HIV infections. A viral load was reported for 298 of 809 cases, with a median of 184,481 copies/mL (IQR: 45,405–983,158). Among these 298 cases, CD4+ T-cell counts were available for 214, with a median of 357 cells/µL (IQR: 278–487). The proportional distribution of recently infected cases analysed by sex, transmission routes, country of origin and country of infection extracted from sociodemographic data submitted with the notification form are shown in Table 1.

Table 1

Characteristics of patients with recent infection included in molecular HIV surveillance, Germany, 2013–14 (n = 809)

Study population n %
Male 718 88.8
Female 86 10.6
Not reported 5 0.6
Transmission group
Men who have sex with men 497 61.4
Persons with heterosexual contacts 65 8.0
Persons with intravenous drug use 21 2.6
Other 6 0.7
Not reported 220 27.2
Country of origin
Germany 485 60.0
Other 158 19.5
Not reported 166 20.5
Country of infection
Germany 523 64.6
Other 91 11.2
Not reported 195 24.1

Prevalence of transmitted drug resistance

The overall prevalence of TDR in patients with recently acquired HIV infection diagnosed in 2013 and 2014 was 10.8% (n = 87/809; 95% CI: 8.8–13.1). This comprised mono-resistance to NRTIs in 4.3% (35/809; 95% CI: 3.1–6.0) of the patients, to NNRTIs in 2.6% (21/809; 95% CI: 1.7–4.0) and to PIs in 3.0% (24/809; 95% CI: 2.0–4.5) of cases. Dual and triple class resistance was identified in 0.6% (n = 4 NRTI/NNRTI; n = 1 NNRTI/PI) and 0.2% (n = 2 NRTI/NNRTI/PI) of the patients, respectively (Table 2).

Table 2

Prevalence of transmitted drug resistance to the major antiretroviral drug classes in the study population stratified by relevant subgroups, Germany, 2013–14 (n = 809)

n % n % n % n % n % n %
Total 87 10.8 35 4.3 21 2.6 24 3.0 5 0.6 2 0.2
Male (n = 718) 78 10.9 32 4.5 18 2.5 21 2.9 5 0.7 2 0.3
Female (n = 68) 9 10.5 3 3.5 3 3.5 3 3.5 0 0
Not reported (n = 5) 0 0 0 0 0 0
Transmission group
MSM (n = 497) 59 11.9 22 4.4 14 2.8 17 3.4 4 0.8 2 0.4
HET (n = 65) 4 6.2 3 4.6 1 1.5 0 0 0
PWID (n = 21) 2 9.5 1 4.8 0 1 4.8 0 0
Other (n = 6) 0 0 0 0 0 0
Not reported (n = 220) 22 10.0 9 4.1 6 2.7 6 2.7 1 0.5 0
Country of origin
Germany (n = 485) 56 11.5 24 4.9 12 2.5 16 3.3 3 0.6 1 0.2
Other (n = 158) 12 7.6 2 1.3 5 3.2 3 1.9 1 0.6 1 0.6
Not reported (n = 166) 19 11.4 9 5.4 4 2.4 5 3.0 1 0.6 0
Country of infection
Germany (n = 523) 63 12.0 23 4.4 15 2.9 18 3.4 5 1.0 2 0.4
Other (n = 91) 5 5.5 3 3.3 1 1.1 1 1.1 0 0
Not reported (n = 195) 19 9.7 9 4.6 5 2.6 5 2.6 0 0
HIV-1 Subtypes
B (n = 623) 75 12.0 33 5.3 16 2.6 19 3.0 5 0.8 2 0.3
Non-B (n = 186) 12 6.5 2 1.1 5 2.7 5 2.7 0 0

HET: persons with heterosexual contact; HIV: human immunodeficiency virus; MSM: men who have sex with men; NRTI: nucleotide reverse transcriptase inhibitors; NNRTI: non-nucleotide reverse transcriptase inhibitors; PI: protease inhibitor; PWID: people who inject drugs; TDR: transmitted drug resistance.

`Not reported´ data were excluded from the pairwise comparisons. All p values of pairwise comparison were > 0.05.

Of all 52 NRTI-associated mutations identified, 46 were thymidine analogue mutations (TAM), namely: the revertants of T215Y (T215CDEISV; 2.3%; 19/809), M41L (2.2%; 15/809), K219ENQR (0.9%; 7/809) and D67EGN (0.6%; 5/809). TAM were selected by the thymidine analogues and conferred intermediate resistance to azidothymidine (AZT) and stavudine (D4T). The most prevalent NNRTI resistance mutations were K103N and K103S (2.5%; 20/809), selected by first generation NNRTIs. The PI-selected resistance mutations M46I and M46L were present at a level of 1.6% (13/809) associated with resistance to a broad spectrum of PIs: atazanavir/ritonavir (ATV/r), fosamprenavir (FPV/r), indinavir (IDV/r), lopinavir (LPV/r), nelfinapir (NFV) and tripranavir (TPV/r). The PI-selected resistance mutations L90M (resistance to LPV/r, ATV/r, saquinavir (SQV)/r, IDV/r, NFV) and V82ACFLTMS (resistance to FPV/r, TPV/r, IDV/r, LPV/r, ATV/r) were present at levels of 0.7% (6/809) and 0.9% (7/809), respectively (Figure 1A and B).

Figure 1

Prevalence of transmitted drug resistance mutations by drug class (A) and predicted susceptibility to antiretroviral drugs by level of resistance (B) in the study population, Germany, 2013–14 (n = 809)


NRTI: nucleoside reverse transcriptase inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; PI: protease inhibitor.

Panel B: Prediction according to Stanford SIR algorithm: intermediate levels of resistance (light colours) and high levels of resistance (dark colours); low and potentially low levels are not indicated.

Drug resistance mutations observed in transmitted HIV strains mainly induced intermediate levels of resistance to NRTI and PI (mainly resistance-associated singleton mutations). High levels of resistance were frequently observed to the NNRTIs efavirenz (EFV) and nevirapine (NVP) and were caused primarily by the prevalent resistance mutation K103N (Figure 1B).

We found no correlation between TDR and sex, transmission group, origin of patient or country of infection in general or for any resistance class (all p values > 0.05) (Table 2).

Prevalence of HIV-1 subtypes

The most prevalent HIV-1 subtype in the total study population (n = 809) was subtype B with 77.0% (623/809; 95% CI: 73.9–79.8), while 23.0% of HIV-1 infections (186/809; 95% CI: 20.2–26.1) were caused by non-B subtypes including A (5.1%, 41/809), C (3.6%, 29/809), D (0.7%, 6/809), F (1.6%, 13/809), G (2.7%, 22/809), CRF01_AE (2.0%, 16/809) and CRF02_AG (3.3%, 27/809) as well as 4.0% (32/809) other rare CRFs (06_cpx, 07_BC, 12_BF, 18_cpx, 19_cpx, 34_01B, 35_AD, 44_BF, 49_cpx) and URFs. These rare CRFs were grouped together with the URFs into the rare CRF/URF subgroup.

The subtype distribution in the subset of recent infections with available CD4+ T-cell counts and viral loads (n = 214) was very similar to the overall study population, with 77.1% (165/214) subtype B and 22.9% (49/214) non-B infections including A (4.2%, 9/214), C (5.1%, 11/214), D (0.9%, 2/214), F (0.9%, 3/214), G (2.8%, 6/214), CRF01_AE (1.9%, 4/214) and CRF02_AG (1.9%, 4/214) as well as 4.7% (10/214) rare CRF/URFs (all p values of pairwise comparisons > 0.2).

HIV-1 subtype B was associated with a significantly higher proportion of TDR (12.0%, 75/623) than the non-B subtypes (6.4%; 12/186; OR: 0.50; 95% CI: 0.27–0.95; p = 0.04), particularly with regard to the NRTI mutations (5.3% in B, 1.1% in non-B, p = 0.01) (Table 2).

With regard to the main transmission groups, MSM were predominantly infected by subtype B, with 87.7% (436/497) which is significantly higher than in PWID (14/21) or in HET (15/65; male HET: 4/19 and female HET 11/46; all p values MSM-PWID-HET < 0.05). In HET, subtype diversity was high and particularly non-B subtypes A (8/65), C (12/65) and G (8/65) were frequent. In PWID, subtype A (4/21) was the second most prevalent subtype (after B with 14/21), while subtypes C, D, CRF01_AE and the group of rare CRF/URF were not identified in PWID. Subtype distribution in the group that did not report transmission type mirrored the group that did report transmission type (MSM + HET + PWID), with a slightly lower proportion of subtype B (70.5%, 155/220 vs 79.8%, 465/583) (Figure 2A). The proportion of subtype non-B infections in Germans (14.0%, 68/485) was significantly lower than in individuals from other countries (45.6%, 72/158; p < 0.0001). Subtype B was predominant in Germans and in migrants originating from America and western and central Europe (417/485, 15/17, 19/28 and 29/36, respectively). Subtype A was the most frequently subtype identified in eastern Europeans (12/27), while migrants from Africa and Asia were infected with a greater variety of subtypes (Figure 2B).

Figure 2

Subtype distribution (A) in the main transmission groups and (B) by country of origin, Germany, 2013–14 (n = 809)


HET: persons with heterosexual contact; HET_f: female persons with heterosexual contact; HET_m: male persons with heterosexual contact; MSM: men who have sex with men; PWID: people who inject drugs.

a Transmission group `other´(n=6, see Table 1) was excluded from the data set.

b Patients from the Middle East, North and sub-Saharan Africa.

c Patients from North and Latin America.

d Patients from South and South-east Asia.

e Two patients from the Caribbean, one patient from Oceania and two patients with unknown non-German origin were excluded.

For the subtypes A, B, F, CRF01_AE and the rare CRF/URF, the main transmission route was MSM (14/41, 436/623, 7/13, 7/16 and 14/32, respectively) while the subtypes C, D and G were mainly transmitted by heterosexual contacts (12/29, 3/6 and 8/22, respectively) (Figure 3A).

Figure 3

Prevalence of HIV-1 subtypes stratified by (A) main transmission groups and (B) origin of patient, Germany 2013–14 (n = 809)


HET: persons with heterosexual contact; MSM: men who have sex with men; PWID: people who inject drugs.

a Transmission group `other´(n=6), see Table 1.

b Patients from South and South-east Asia.

c Patients from North and Latin America.

d Patients from Middle East, North and sub-Sahara Africa.

e Two patients from the Caribbean, one patient from Oceania and two patients with unknown non-German origin were excluded.

HIV subtype A was mostly identified in Germans (16/41) and eastern European patients (12/41), subtype C and G in Germans (12/29 and 6/22) and Africans (8/29 and 6/22), while for Subtype D and CRF02_AG, no main origin of patients could be identified. The rare CRF/URFs were mainly identified in Germans (14/31) but also in patients originating from other continents (Europe (4/31), Africa (3/31), America (2/31) and Asia (1/31)) (Figure 3B).

A stratification according to the geographical region of acquisition revealed that in Germany (86.2%; 451/523), America (3/5) and in western (14/21) and central Europe (7/12), subtype B infections were mainly acquired. Non-B subtypes were acquired more frequently abroad (62.6%; 57/91) than in Germany (13.8%; 72/523; p < 0.05).


We have established a molecular HIV-1 surveillance strategy based on samples collected in association with the mandatory notification system of new HIV diagnoses in Germany. Analysis of samples was restricted to recent HIV-transmissions with a defined duration of less than 302 days since HIV infection. This approach permitted us to focus on the viruses circulating during any given period of time and to estimate current trends in the HIV epidemic, because late presenters who acquired an infection before that period were excluded.

The overall TDR prevalence among the 2013 and 2014 study samples was 10.8%. This is largely comparable to previously published cohort studies from Germany and several other western European countries with a long history of combination ART (cART) [3-5] and indicates in many respects that the rate of TDR is essentially stable: Patients included in the German HIV-1 seroconverter cohort between 1996 and 2010 revealed TDR in 11.9% [5]. Two recent comprehensive epidemiological studies involving 26 European countries carried out on behalf of the SPREAD-programme reported levels of 8.9% (95% CI: 8.1–9.8) and 8.3% (95% CI: 7.7–9.5) for the period from 2002 to 2007 [6] and from 2008 to 2010, respectively [12]. Proportions of patients with mono-NRTI, mono-NNRTI, mono-PI, dual- and multi-class resistance (5.0%, 2.9%, 2.5%, 0.8% and 0.4%, respectively) [6] were very similar to our findings (4.3%, 2.6%, 3.0%, 0.6% and 0.2%). In both the SPREAD studies and in ours, the detected NRTI resistance mutations belonged to the TAM (mainly revertants of T215Y, followed by M41L) selected by AZT and D4T. The most prevalent NNRTI SDRMs were K103NS, and resistance to PIs was mainly due to the mutations L90M and M46IL [6,12]. TAM are very frequent and long-term persisting resistance mutations [8]. De novo selection by current therapies is unlikely because the use of AZT and D4T is declining [13]. We therefore suggest that these have become circulating strains by onward transmission from untreated, and probably undiagnosed, individuals. While TAM may not have any particular impact on the success of current first-line treatments, K103N and K103S may still be associated with their failure [7].

Sex was not associated with TDR in our study. However, the prevalence of TDR was slightly but not significantly higher among MSM, in Germans or in individuals infected in Germany. In studies carried out in some other European countries, the associations between TDR and MSM or subtype B (exhibiting higher TDR levels) were significant [6,12,14].

HIV-1 epidemiology is characterised by compartmentalised subepidemics of subtypes with a dynamic nature. The most prevalent subtype in western European countries is subtype B, mainly as a consequence of multiple introductions via migration, tourism and trade from different geographical areas [15]. The lowest proportion of subtype B was reported for Portugal with 48.3% for patients diagnosed between 2006 and 2012 [16] while the highest proportion was observed in Poland with 96.2% for patients diagnosed between 2002 and 2005 [17].

Determinants of subtype distribution are the transmission group, country of origin and country of infection. Subtype B is highly prevalent in MSM, most probably as a result of a founder effect rather than an increased transmission potential of subtype B [18]. Non-B subtypes were significantly more frequently diagnosed in sub-populations originating from and often acquired in countries other than Germany. Most migrants with recent HIV infections carried subtypes dominating in their country of origin [19], suggesting that they may have acquired the infection during a visit to their home countries or within their community in Germany.

Interestingly, a considerable proportion of rare CRF/URFs are present in patients originating from all continents. However, the high proportion of Germans in the non-B clade group, in particular those with subtype A, F and rare CRF/URFs, indicates that non-B strains have become endemic in the German population. Although the number of PWID analysed was low, HIV-1 subtype A was strikingly more common in PWID than in other transmission groups.

One limitation of our study was that the restriction to recently acquired infections over-estimates patient groups that are tested more frequently due to their awareness of transmission risks. This might explain the slightly higher prevalence of MSM among recent infections in our study (61.4%) compared with the notification data for all (recent and prevalent) newly diagnosed HIV infections in 2013 and 2014 (57.7%) [20]. A second limitation was the overall genotyping success rate of 58% in samples from recent infections. This was mainly due to a lack of serum spots for RNA extraction or to RNA degradation after inappropriate handling or shipment. A technical limitation was the expected misclassification of long-standing as recent infections due to a false recent rate (FRR) of ca 4.7% for subtype B or even higher for the non-B subtypes, in particular A and D (FRR 18.9 and 18.2%, respectively), using the BED CEIA assay [21]. This may have led to an over-representation of non-B subtypes in the study. Taking into account CD4+ T-cell counts and viral load data as parameters for recency estimation is expected to diminish this bias [22]. Consideration of these clinical parameters that were available for about one third of the samples only marginally reduced the prevalence for the recent non-B infections from 23.0% to 22.9% but, more significantly, from 5.1% to 4.2% for subtype A, which is generally the most strongly affected by BED misclassification. An ancillary analysis of specimens that were reclassified as long-standing infections based on CD4+ T-cell counts < 200 cells/µL and viral loads < 400 copies/mL (n = 72) revealed 33.3% non-B and 11.1% subtype A (data not shown), confirming the anticipated over-representation introduced by the BED ELISA. Based on these data, the lack of CD4+ T-cell counts and viral loads for two thirds of the sample set is estimated to result in an over-representation of non-B subtypes of less than 2.5%. Being one of two commercially available recency tests, the BED CEIA is used worldwide for epidemiological surveillance studies [23-28], although efforts to evaluate and improve serological recency tests are ongoing [21].


The TDR prevalence in recent HIV infections among notified newly diagnosed HIV patients in Germany was still high (> 10%) in 2013 and 2014 and was within the range of other European countries, including the proportions of resistance classes. Although the selection for resistant HIV was dramatically reduced by the introduction of cART and new drugs [29], levels of TDR remain stable in all European countries and are still dominated by resistance to NRTI. This is most likely caused by a continued onward transmission of persisting NRTI-resistant strains that emerged as a result of failed treatment regimens during the pre-cART era (1987–96) and not by transmission of resistant viruses from patients failing cART. Therefore, genotypic resistance testing of HIV before first-line treatment needs to be continued. Since therapy-naïve and probably also undiagnosed patients are the predominant source of TDR, early detection of HIV infection followed by early treatment, as recommended in the current guidelines [7], could reduce the transmission of resistant virus [13,30]. Our data also demonstrate that subtype B remains the most frequently transmitted subtype in Germany because of its high prevalence in MSM.


The authors thank the laboratories participating in the InzSurv and MASTER HIV/HEP projects. We also thank the sequencing facility of the RKI. Many thanks to Steve Norley for proofreading of the manuscript. The study was funded by the German Federal Ministry of Health.

Conflict of interest

None declared.

Authors’ contributions

Andrea Hauser: designed and performed the experiments, collected data, analysed the data, wrote the manuscript. Alexandra Hofmann: collected and analysed data; contributed to the writing of the manuscript. Kirsten Hanke: analysed the data. Viviane Bremer: analysed the data, contributed to the writing of the manuscript. Barbara Bartmeyer: collected and analysed data, contributed to the writing of the
manuscript. Claudia Kuecherer: contributed significantly to the design of the study, contributed
reagents/materials/analysis tools; analysed the data, contributed to the writing of the
manuscript. Norbert Bannert: was mainly responsible for the design and supervision of the study,
analysed the data, contributed to the writing of the manuscript.


  1. Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A,  et al.  Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11(5):363-71. DOI: 10.1016/S1473-3099(11)70032-9 PMID: 21354861

  2. Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR,  et al.  Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010;24(8):1203-12. DOI: 10.1097/QAD.0b013e3283388742 PMID: 20395786

  3. Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V,  et al.  Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect. 2012;18(8):E299-304. DOI: 10.1111/j.1469-0691.2012.03847.x PMID: 22536753

  4. Baxter JD, Dunn D, White E, Sharma S, Geretti AM, Kozal MJ,  et al.  Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16(Suppl 1):77-87. DOI: 10.1111/hiv.12236 PMID: 25711326

  5. Zu Knyphausen F, Scheufele R, Kücherer C, Jansen K, Somogyi S, Dupke S,  et al.  First line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter study. PLoS One. 2014;9(5):e95956. DOI: 10.1371/journal.pone.0095956 PMID: 24788613

  6. Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB,  et al.  Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014;14(1):407. DOI: 10.1186/1471-2334-14-407 PMID: 25047543

  7. European AIDS Clinical Society (EACS). Guidelines. Version 8.0. European Guidelines for treatment of HIV-infected adults in Europe2015. Brussels: EACS; October 2015. Available from:

  8. Yang WL, Kouyos RD, Böni J, Yerly S, Klimkait T, Aubert V,  et al. , Swiss HIV Cohort Study (SHCS). Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds.PLoS Pathog. 2015;11(3):e1004722. DOI: 10.1371/journal.ppat.1004722 PMID: 25798934

  9. Cleland A, Davis C, Adams N, Lycett C, Jarvis LM, Holmes H,  et al.  Development of multiplexed nucleic acid testing for human immunodeficiency virus type 1 and hepatitis C virus. Vox Sang. 2001;81(2):93-101. DOI: 10.1046/j.1423-0410.2001.00093.x PMID: 11555468

  10. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification.Nucleic Acids Res. 2014;42(18):e144. DOI: 10.1093/nar/gku739 PMID: 25120265

  11. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M,  et al.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4(3):e4724. DOI: 10.1371/journal.pone.0004724 PMID: 19266092

  12. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D,  et al.  Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016;62(5):655-63. DOI: 10.1093/cid/civ963 PMID: 26620652

  13. Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane PA, UK HIV Drug Resistance Database. Evidence of self-sustaining drug resistant HIV-1 lineages among untreated patients in the United Kingdom.Clin Infect Dis. 2015;61(5):829-36. DOI: 10.1093/cid/civ393 PMID: 25991470

  14. Karlsson A, Björkman P, Bratt G, Ekvall H, Gisslén M, Sönnerborg A,  et al.  Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One. 2012;7(3):e33484. DOI: 10.1371/journal.pone.0033484 PMID: 22448246

  15. Magiorkinis G, Angelis K, Mamais I, Katzourakis A, Hatzakis A, Albert J,  et al.  The global spread of HIV-1 subtype B epidemic. Infect Genet Evol. 2016;46:169-79.

  16. Pereira NR, Duro R, Piñero C, Malheiro L, Soares J, Serrão R,  et al.  Characterization of HIV-1 subtypes in a Portuguese cohort. J Int AIDS Soc. 2014;17(4) Suppl 3;19683.PMID: 25397433

  17. Abecasis AB, Wensing AM, Paraskevis D, Vercauteren J, Theys K, Van de Vijver DA,  et al.  HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology. 2013;10(1):7. DOI: 10.1186/1742-4690-10-7 PMID: 23317093

  18. Foley B, Pan H, Buchbinder S, Delwart EL. Apparent founder effect during the early years of the San Francisco HIV type 1 epidemic (1978-1979).AIDS Res Hum Retroviruses. 2000;16(15):1463-9. DOI: 10.1089/088922200750005985 PMID: 11054259

  19. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.AIDS. 2006;20(16):W13-23. DOI: 10.1097/01.aids.0000247564.73009.bc PMID: 17053344

  20. Robert Koch Institute (RKI). Regional distribution of new HIV diagnoses within Germany. [Regionale Verteilung der HIV-Neudiagnosen innerhalb Deutschlands]. Epidemiologisches Bulletin. 2015;27/2015. German. Available from:

  21. Kassanjee R, Pilcher CD, Keating SM, Facente SN, McKinney E, Price MA,  et al.  Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS. 2014;28(16):2439-49. DOI: 10.1097/QAD.0000000000000429 PMID: 25144218

  22. European Centre for Disease Prevention and Control (ECDC). Monitoring recently acquired HIV infections in the European context. Stockholm: ECDC; 2013. Available from:

  23. Kim AA, McDougal JS, Hargrove J, Rehle T, Pillay-Van Wyk V, Puren A,  et al.  Evaluating the BED capture enzyme immunoassay to estimate HIV incidence among adults in three countries in sub-Saharan Africa. AIDS Res Hum Retroviruses. 2010;26(10):1051-61. DOI: 10.1089/aid.2009.0218 PMID: 20849299

  24. Scheer S, Nakelsky S, Bingham T, Damesyn M, Sun D, Chin CS,  et al.  Estimated HIV Incidence in California, 2006-2009. PLoS One. 2013;8(2):e55002. DOI: 10.1371/journal.pone.0055002 PMID: 23405106

  25. Grinberg G, Giron LB, Knoll RK, Galinskas J, Camargo M, Arif MS,  et al.  High prevalence and incidence of HIV-1 in a counseling and testing center in the city of Itajaí, Brazil. Braz J Infect Dis. 2015;19(6):631-5. DOI: 10.1016/j.bjid.2015.08.001 PMID: 26361837

  26. Zhang J, Guo Z, Yang J, Pan X, Jiang J, Ding X,  et al.  Genetic diversity of HIV-1 and transmitted drug resistance among newly diagnosed individuals with HIV infection in Hangzhou, China. J Med Virol. 2015;87(10):1668-76. DOI: 10.1002/jmv.24223 PMID: 25899877

  27. Lunar MM, Matković I, Tomažič J, Vovko TD, Pečavar B, Poljak M. Longitudinal trends of recent HIV-1 infections in Slovenia (1986-2012) determined using an incidence algorithm.J Med Virol. 2015;87(9):1510-6. DOI: 10.1002/jmv.24209 PMID: 25970253

  28. Santos-Hövener C, Zimmermann R, Kücherer C, Bätzing-Feigenbaum J, Wildner S, Hamouda O,  et al.  Conversation about Serostatus decreases risk of acquiring HIV: results from a case control study comparing MSM with recent HIV infection and HIV negative controls. BMC Public Health. 2014;14(1):453. DOI: 10.1186/1471-2458-14-453 PMID: 24885694

  29. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, Hogg RS,  et al.  Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis. 2010;50(1):98-105. DOI: 10.1086/648729 PMID: 19951169

  30. Drescher SM, von Wyl V, Yang WL, Böni J, Yerly S, Shah C,  et al.  Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study. Clin Infect Dis. 2014;58(2):285-94. DOI: 10.1093/cid/cit694 PMID: 24145874

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.